Medical Therapy of Pediatric Glaucoma and Glaucoma in Pregnancy
|
|
- Denis Edwards
- 5 years ago
- Views:
Transcription
1 Ophthalmol Clin N Am 18 (2005) Medical Therapy of Pediatric Glaucoma and Glaucoma in Pregnancy PeterJ.G.Maris,Jr,MD a, Anil K. Mandal, MD b, Peter A. Netland, MD, PhD a, * a Hamilton Eye Institute, University of Tennessee Health Science Center, 930 Madison Avenue, Suite 100, Memphis, TN 38163, USA b Jasti V. Ramanamma Children s Eye Care Center, L.V. Prasad Eye Institute, Hyderabad, India Medical therapy is usually allocated to a supportive role in the management of pediatric glaucoma patients. In children, medical therapy is used to reduce intraocular pressure temporarily or to clear the cornea so that surgical therapy, the definitive treatment for primary congenital glaucoma, can be undertaken. Those patients who do require long-term medical therapy usually have intractable disease that has not responded adequately to surgical therapy. Our purpose is to review medical therapy of pediatric patients. We also review medical treatment of glaucoma in pregnant women, considering the risks and benefits of treatment of the patient and potential adverse effects on the fetus. Medical therapy of pediatric glaucoma Some children with congenital glaucoma and elevated intraocular pressure respond well to medical therapy. In 161 eyes with congenital glaucoma, medical therapy by itself reduced the intraocular pressure to less than 21 mm Hg in 12% of eyes in the short term and 10% of eyes in the long term [1]. When considering medical therapy in pediatric patients, clinicians should evaluate the risks and benefits of specific medications, use the minimum dosages P.A. Netland receives research support from Alcon, Allergan, Merck, and Pfizer. * Corresponding author. address: mesmith@utmem.edu (P.A. Netland). required for therapeutic efficacy, and follow the patient closely for ocular and systemic side effects [2,3]. Although regulatory agencies worldwide do not typically include children in antiglaucoma drug approval studies, clinicians have found several medications to be useful in treating children with elevated intraocular pressure (Box 1). Evidence has appeared in the literature regarding the efficacy and safety of different classes of glaucoma medications. Carbonic anhydrase inhibitors In adult patients, the side effects of systemic carbonic anhydrase inhibitors are well known to clinicians. In children, growth suppression has been associated with oral acetazolamide therapy, and infants may experience severe metabolic acidosis [4,5]. Side effects from the use of systemic carbonic anhydrase inhibitors in infants and young children are not commonly reported, although these patients may not verbalize the occurrence of side effects to their parents or health care providers. Oral administration of acetazolamide suspension at a dosage of 10 (range: 5 15) mg/kg/d in divided doses (three times daily) is usually tolerated by children, reduces intraocular pressure, and diminishes corneal edema before surgery [6,7]. Topical versus oral carbonic anhydrase inhibitor therapy has been evaluated for pediatric glaucoma in a crossover design study [8]. The mean intraocular pressure was reduced by 36% and 27% compared with baseline after treatment with oral acetazolamide /05/$ see front matter D 2005 Elsevier Inc. All rights reserved. doi: /j.ohc ophthalmology.theclinics.com
2 462 Box 1. Glaucoma medications commonly used in childhood glaucoma Beta-blockers Betaxolol 0.% (every day, twice daily) Levobunolol 0.% (every day, twice daily) Timolol solution 0.% (every day, twice daily) Timolol gel-forming solution 0.% (every day) Carbonic anhydrase inhibitors Acetazolamide elixir, 5 to15 mg/kg/d in divided doses (twice daily, three times daily) Brinzolamide 1% (twice daily, three times daily) Dorzolamide 2% (twice daily, three times daily) Cholinergic drugs Pilocarpine 1%, 2% (three times daily, four times daily) Prostaglandin-related drugs Bimatoprost 0.03% (every day) Latanoprost 0.005% (every day) Travopost 0.004% (every day) maris et al and topical dorzolamide, respectively (Fig. 1). Although not as effective as acetazolamide in this group of patients, topical dorzolamide caused a significant reduction in intraocular pressure [8]. Furthermore, treatment with topical dorzolamide caused few side effects. One patient noted a burning sensation after installation during the first month of use, but none experienced corneal toxicity or allergic symptoms. Presently, topical carbonic anhydrase inhibitors are more widely prescribed compared with systemic carbonic anhydrase inhibitors. Many clinicians prefer twice-daily dosing to minimize the discomfort and inconvenience to the parent and the child associated with three times daily dosing. Taking the fixed combination of dorzolamide with timolol twice a day can simplify the medical regimen by reducing the number of drops instilled per day and may be more appropriate for older children. Beta-blockers Adjunctive treatment with timolol has been studied in patients with a variety of pediatric glaucomas. In 34 patients with childhood glaucoma, timolol was combined with other medical therapy, causing a definite improvement in 29%, a modest or equivocal improvement in 32%, and no improvement in 39% [9]. In 38 eyes being treated with timolol as adjunctive therapy, 37% of eyes were controlled at 22 mm Hg or lower [10]. In 89% of eyes with various types of pediatric glaucoma, lowering of intraocular A IOP (mmhg) Baseline Acetazolamide Dorzolamide B Dorzolamide (% Decrease IOP) Acetazolamide (% Decrease IOP) Fig. 1. Carbonic anhydrase inhibitors in pediatric patients treated with a beta-blocker at baseline. (A) Intraocular pressure (IOP) was significantly reduced from baseline (on a topical beta-blocker alone) after addition of acetazolamide (mean ± standard deviation decrease of 35.7% ± 15.6%) or dorzolamide (27.4% ± 17.1%). Y error bars indicate standard error of mean. Asterisk indicates P <.01 compared with baseline. (B) Correlation between efficacy of oral and topical carbonic anhydrase inhibitor therapy. The percentage reduction of IOP in eight eyes on topical beta-blocker therapy was similar after the addition of acetazolamide (oral) or dorzolamide (topical) treatment (r = 0.94). (Adapted from Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS 1998;2:43 7; with permission.)
3 pediatric glaucoma and glaucoma in pregnancy 463 pressure was achieved only in 20% of eyes [11]. Similarly, in 100 eyes with childhood glaucoma treated with timolol, 31% experienced a reduction of intraocular pressure (Fig. 2) [12]. After the initial response, however, increased intraocular pressure may occur over time [10]. Plasma timolol levels in children after treatment with 0.% timolol greatly exceed those in adults after instillation of 0.5% timolol, particularly in infants [13]. Increased plasma timolol levels in children are explained by the volume of distribution of the drug, which is much smaller in children compared with adults. The ocular volume of the neonate is approximately half that of the adult, reaching full size by approximately 2 years, whereas the blood volume of the neonate as a function of body weight is only a small fraction of that of the adult. Thus, administering the usual adult ocular dosage may be needed for the eye; however, when it is systemically absorbed, the dosage is diluted by a much smaller volume of blood. A B Change IOP (mmhg) Additional treatment required No added treatment > 10 1 to 10 No Change -1 to -10 < Percent Eyes Percent Eyes Fig. 2. Timolol in pediatric glaucomas. (A) In a series of 100 eyes treated with timolol maleate, most (60%) required additional surgery or medications. (B) The change from baseline intraocular pressure (IOP) in the 40 eyes receiving timolol therapy without additional surgery or medications. Of the 40 eyes that received timolol therapy without additional surgery or medications, 31 (78%) demonstrated reduced intraocular pressure (IOP) after timolol treatment. (Adapted from Hoskins Jr HD, Hetherington Jr J, Magee SD, et al. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol 1985;103:1163 5; with permission.) In addition, the infant s immature metabolic enzyme systems may prolong the half-life of drugs in the neonate from two to six times beyond that of the typical adult [14]. Higher plasma levels of drug in infants and children would be expected to increase the risk of systemic side effects as compared with adults. In children older than 5 years of age, a reduction in resting pulse rates has been associated with timolol use and is comparable to that of adults [9]. Side effects have occurred in 4% to 13% of children [10,11], and timolol therapy has been discontinued in 3% to 7% of patients [9,10]. Alarming side effects of timolol therapy, such as Cheyne-Stokes breathing and apneic spells, have been reported, especially in infants and younger children [15 17]. Provocation of asthma has been associated with timolol treatment. Betaxolol, a selective b 1 antagonist, reduces the risk of pulmonary side effects in adults as compared with timolol, but its effect on children is not known. Likewise, the effects of long-term use of any of the topical beta-blockers in children have not been reported. Timolol in 0.% and 0.5% solutions should be used cautiously in young glaucoma patients. Because of the possibility of apnea, the drug should be used with extreme caution in neonates. A detailed pediatric history and examination to elicit the presence of systemic abnormalities, such as bronchial asthma and cardiac disease, should precede the use of timolol. In such cases, therapy with a beta-blocker is contraindicated. The use of 0.% timolol instead of 0.5% timolol is strongly recommended to reduce the risk of side effects. Additionally, a significant reduction in the systemic absorption of timolol has been observed when performing punctal occlusion and simple eyelid closure after drop administration [13]. Although the practice of punctal occlusion with the eyelids closed for at least 1 minute may be considerably more difficult to execute in children than in adults, simply blotting off excess drops from the child s lids may help to minimize unwanted systemic absorption [13]. Once-daily dosing with timolol 0.% in a gelforming solution may similarly help to simplify the medical regimen. a 2 Agonists Several noncomparative case series describing the use of brimonidine in pediatric glaucoma patients exist in the ophthalmic literature, whereas the pediatric use of apraclonidine has not been described. In 30 patients with a mean age of 10 years, brimonidine treatment achieved a mean 7% reduction in intraocular pressure from baseline [18]. Two young
4 464 maris et al children (aged 2 and 4 years) were transiently unarousable after administration of brimonidine, and five other children experienced severe fatigue [18]. In a study of 23 patients with a mean age of 8 years, 18% experienced serious systemic adverse effects necessitating cessation of the drug [19]. Four pediatric patients have been reported to develop somnolence after treatment with brimonidine [20]. Additionally, a 1-month-old infant experienced repeated episodes of coma, characterized by unresponsiveness, hypotension, hypotonia, hypothermia and bradycardia after treatment with brimonidine [21]. The a 2 agonists are less often used in pediatric patients compared with adult patients. The possibility of central nervous system mediated side effects is greater with lipophilic drugs (eg, brimonidine) than for more hydrophilic drugs (eg, apraclonidine), which are less likely to cross the blood-brain barrier. Iopidine may help to minimize intraoperative hyphema precipitated by goniotomy [22]. Brimonidine should be used cautiously in pediatric patients, and its use should be restricted to older children. Other adrenergic agonists Although uncommonly prescribed at present as an ocular hypotensive agent in the adult population, epinephrine (1%) has been used in children [23]. Lack of efficacy as well as the potential for systemic toxicity, including cardiac tachyarrhythmia and hypertension, limit the use of this drug. When used, a reactive conjunctival hyperemia may occur after the initial a 1 -mediated vasoconstriction. After prolonged use of topical epinephrine (1%), melanin-like adrenochrome deposits consisting of oxidation products of the compound may be noted in the conjunctiva and occasionally in the cornea. Dipivefrin hydrochloride 0.1%, a prodrug of epinephrine, may also be used in pediatric patients. Given its prodrug composition, side effects may be attenuated compared with epinephrine. Still, local allergic reactions occur frequently. These drops are administered every 12 to 24 hours. Epinephrine (1%) and dipivefrin hydrochloride 0.1% should be avoided in aphakic or pseudophakic pediatric patients because of the risk of cystoid macular edema. Cholinergic drugs Although miotic drugs enhance aqueous outflow through the trabecular meshwork in normal patients as well as in glaucoma patients, thereby lowering intraocular pressure, these drugs are likely not as effective in developmental glaucoma. This reduced efficacy in developmental glaucoma is believed to be attributable to the abnormal insertion of the ciliary muscle into the trabecular meshwork. In pediatric patients, the use of pilocarpine (2% applied every 6 8 hours) has been limited [6]. These drugs may benefit aphakic and pseudophakic children with elevated intraocular pressure, however. In addition, cholinergic drugs serve a useful purpose in the surgical management of pediatric glaucoma by causing pupillary miosis before and after goniotomy [22]. The induced myopia produced by miotic therapy can cause disabling visual difficulties. A slow-release pilocarpine membrane delivery system, Ocusert (Alza Pharmaceuticals, Palo Alto, California), currently not available from the manufacturer, was helpful in some young patients [24], and the sudden release of pilocarpine (burst effect) seldom induced myopic spasms. The long-acting anticholinesterase drugs are not readily available, are associated with serious adverse effects, and offer no advantages over pilocarpine for use in pediatric glaucoma. Echothiophate iodide (phospholine iodide), usually administered topically every 12 to 24 hours, is a potent and relatively irreversible inhibitor of the enzyme cholinesterase. Ciliary spasm and angle-closure glaucoma have been precipitated by the use of echothiophate iodide to treat esotropia in a child []. Also, the systemic absorption of anticholinesterase agents can significantly reduce the serum cholinesterase and pseudocholinesterase levels. Affected patients, particularly children, may show signs of excessive parasympathetic nervous system activation. These signs can include generalized weakness, diarrhea, nausea, vomiting, excessive salivation, and decreased heart rate. Significantly reduced systemic levels of cholinesterase and pseudocholinesterase can be particularly dangerous when surgery is contemplated, because succinylcholine is commonly used as a muscle relaxant during general anesthesia. Succinylcholine is normally quickly hydrolyzed by systemic cholinesterase at nerve endings. When serum cholinesterase levels are low, however, prolonged apnea can result because of this excess of unhydrolyzed succinylcholine. Prostaglandin-related drugs Prostaglandin-related drugs, specifically latanoprost, have been evaluated in studies of a variety of glaucoma diagnoses, including glaucoma associated with Sturge-Weber syndrome [26 30]. In 31 eyes with a variety of glaucoma diagnoses, 6 (19%) of the treated eyes responded with a mean reduction in intraocular pressure of 8.5 mm Hg, which represented a 34% decrease from baseline. Most eyes were
5 pediatric glaucoma and glaucoma in pregnancy 465 A Number Eyes B 35 0 Nonresponders Responders 30 IOP (mmhg) 20 Nonresponders Responders Baseline Latanoprost Fig. 3. Latanoprost in pediatric glaucomas. (A) In a series of 31 eyes, most children (n = ) were nonresponders (defined as <15% decrease in intraocular pressure [IOP]). Medical therapy using any particular drug is usually effective in a few pediatric glaucoma patients. (B) In 31 eyes, latanoprost was effective in six responders (defined as 15% decrease in IOP). The average IOP reduction in latanoprost responders was 8.5 ± 3.6 mm Hg (34.0% ± 10.9%; asterisk denotes P =.002). Y error bars indicate standard deviation. (Adapted from Enyedi LB, Freeman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS 1999;3:33 9; with permission.) nonresponders, however (Fig. 3). Subjects who responded favorably were more likely to have juvenileonset open-angle glaucoma and to be older than nonresponders [26]. The drug was well tolerated in this short-term study. In glaucoma associated with Sturge-Weber syndrome, 17% to 28% of eyes treated with latanoprost responded with a reduction in intraocular pressure [27,28]. Increased episcleral venous engorgement was noted, and one patient (6%) discontinued latanoprost therapy because of intolerable hyperemia of the conjunctiva [28]. Although a decline in success over time was noted, half of the patients were controlled at 1 year of follow-up after a trial of latanoprost as adjunctive therapy [29]. Although most children do not respond well to latanoprost therapy, some children may experience an appreciable hypotensive effect with treatment [30]. Likewise, the once-daily dosing schedule for latanoprost is convenient. Although local side effects are infrequent and mild, parents and patients should be warned about them, including iris pigmentation changes, eyelash growth, and hyperemia. When short-term medical therapy is planned, such as before surgery, these local side effects are usually not a problem. The prevalence and types of side effects associated with long-term latanoprost use are not known, however. Osmotic drugs Glycerol is administered orally at a dose of 0.75 to 1.5 g/kg of body weight in a 50% solution [31]. The excessively sweet taste may be partially masked by chilling the solution over ice or by using fruit juice (commonly lemon or orange) or flavored water as a diluent. This drug is not commonly used in the treatment of developmental glaucoma. Mannitol (20% solution) is dosed intravenously at 0.5 to 1.5 g/kg of body weight at approximately 60 drops per minute. A rapid fall in intraocular pressure occurs in 20 to 30 minutes after drug administration and can last for 4 to 10 hours. Mannitol may also be used to reduce markedly elevated intraocular pressure before surgery in patients with developmental glaucomas refractory to standard medical therapy.
6 466 maris et al Glaucoma in pregnancy Although glaucoma in adults is primarily a disease of the older population, it can affect women of childbearing age. In managing the pregnant glaucoma patient with medical therapy, one must consider not only the systemic side effects on the mother but any potentially harmful effects on the developing fetus. Based on the limited available literature on the subject, the risk associated with prescribing ophthalmic drops to pregnant women is low [32]. Clinicians should consult experts in the field when in doubt about any deleterious effects of ophthalmic medications, however. Glaucoma is rarely first discovered during pregnancy because intraocular pressure is usually noted to decrease during pregnancy and stays decreased for several months postpartum [33,34]. This reduction in intraocular pressure has been proposed to be caused by several factors: an increase in uveoscleral outflow based on changes in the mother s endogenous hormone levels, a decrease in episcleral venous pressure reflecting an overall reduction of venous pressure in the upper extremities, and a slight metabolic acidosis induced by the mother s pregnant state [35]. This hypotensive effect is believed to increase slightly during the course of the pregnancy. In one study of a group of pregnant women, the mean intraocular pressure in the third trimester was demonstrated to be 1.5 mm Hg lower than in the first trimester [36]. Little is known regarding the teratogenic effects of the commonly prescribed glaucoma medications, and few human studies have specifically examined the potential for harm rendered by the topically applied glaucoma medications. The information that does exist on the subject has been extrapolated from studies of adverse effects attributable to systemic treatment with various agents. For example, a large collaborative study examining the use of systemic cholinergic drugs (eg, pilocarpine) found no association between their use during the first 4 months of gestation and congenital abnormalities [37]. Systemic adrenergic compounds (analogues of topical epinephrine 1% and dipivefrin) have been shown to inhibit the spontaneous and oxytocin-induced contractions of the human uterus, however, and may delay the second stage of labor or cause a prolonged period of uterine atony with hemorrhage [37]. The US Food and Drug Administration (FDA) and other groups specify safety in pregnancy according to categories or classes based on human and animal studies. Class A indicates that safety is established using human studies. Class B indicates presumed safety based on animal studies. Class C indicates uncertain safety, with no human studies and animal studies showing an adverse effect. Class D indicates unsafe, with evidence of risk that may be justifiable in certain clinical circumstances. Class X indicates highly unsafe, with the risk of use outweighing any possible benefit. No topical ophthalmic drugs are placed in category A or X. Most topical glaucoma medications belong to the pregnancy category C (Fig. 4), deemed as having uncertain safety because of adverse fetal effects in animals. Brimonidine and dipivefrin have been ascribed class B status, which presumes safety based on animal studies only. What specifically may confer the additional safety of these two compounds, although similar agents, such as apraclonidine, remain class C, is not apparent when reviewing the literature, however. The fixed-combination timolol 0.5%/dorzolamide 2% has been designated category D. Prostaglandin-related drugs are in pregnancy category C because of adverse fetal effects in animals. Use of the prostaglandin-f 2 a analogues during pregnancy arouses concern because of their presumed abortifacient actions [38]. Manufacturer reports indicate that % of pregnant rabbits exposed to 80 times the human dose of latanoprost delivered no viable fetus at term (FDA latanoprost prescribing information [NDA /S-023]; available at: http//www. fda.gov/cder/approval/x.htm). One observational study of 11 pregnant women revealed no systemic side effects threatening abortion or preterm delivery as a consequence of topical exposure, however [39]. Although this series was too small to achieve statistical significance, the study found no evidence of adverse effects of topical once-daily latanoprost therapy on pregnancy or neonatal outcomes. If the new mother plans on nursing her infant, it is important to consider the excretion of any maternally administered glaucoma medications in her breast milk and their effect on the infant. Clinical evidence Fig. 4. These glaucoma medications are designated pregnancy class C (uncertain safety; adverse fetal effects demonstrated in animals).
7 pediatric glaucoma and glaucoma in pregnancy 467 does exist for the excretion of timolol 0.5% and betaxolol in a nursing mother s breast milk [37]. In the case of timolol 0.5%, the concentration of timolol in the mother s milk was determined to be a factor of one eightieth of the cardiac-effective dose [40]. This level of timolol should probably not cause concern unless the infant s hepatic or renal function is impaired. Nevertheless, if timolol treatment in a nursing mother is deemed absolutely necessary, the infant should be closely observed for signs of beta-blockade or should be weaned altogether. Summary The primary goals of medical therapy in pediatric glaucoma are to decrease intraocular pressure temporarily, to clear an edematous cornea, and to facilitate surgical intervention. Most pediatric patients who require long-term medical therapy have severe disease that has not responded sufficiently to surgical therapy, and these patients may experience additional intraocular pressure reduction with a medical regimen. Before commencing medical glaucoma therapy in a child, clinicians need to consider the potential for side effects carefully. During treatment, children need to be closely monitored because they may be at increased risk of systemic side effects compared with adults as a result of their reduced body mass and blood volume for drug distribution. Similar caution should be exercised when treating the pregnant glaucoma patient or the nursing mother. References [1] Turach ME, Aktan G, Idil A. Medical and surgical aspects of congenital glaucoma. Acta Ophthalmol Scand 1995;73: [2] Wallace DK, Steinkuller PG. Ocular medications in children. Clin Pediatr 1998;37: [3] Palmer EA. How safe are ocular drugs in pediatrics? Ophthalmology 1986;93: [4] Fugati Y, Otani K, Abe J. Growth suppression in children receiving acetazolamide with antiepileptic drugs. Pediatr Neurol 1996;15: [5] Ritch R. Special therapeutic situations. In: Netland PA, Allen RC, editors. Glaucoma medical therapy: principles and management. San Francisco, CA7 American Academy of Ophthalmology; p [6] Hass J. Principles and problems of therapy in congenital glaucoma. Invest Ophthalmol 1968;7: [7] Shaffer RN. New concepts in infant glaucoma. Trans Ophthalmol Soc UK 1967;87: [8] Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS 1998;2:43 7. [9] Boger III WP, Walton DS. Timolol in uncontrolled childhood glaucomas. Ophthalmology 1981;88:3 8. [10] McMahon CD, Hetherington Jr J, Hoskins Jr HD, et al. Timolol and pediatric glaucomas. Ophthalmology 1981;88: [11] Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol 1983;28(Suppl): [12] Hoskins Jr HD, Hetherington Jr J, Magee SK, et al. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol 1985;103: [13] Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984;91: [14] Harte VJ, Timoney RF. Aspects of the prescribing of drugs for children. Pharm Int 1981;2(6): [15] Burnstine RA, Felton JL, Ginther WH. Cardiorespiratory reaction to timolol maleate in a pediatric patient: a case report. Ann Ophthalmol 1982;14: [16] Bailey PL. Timolol and postoperative apnea in neonates and young infants. Anesthesiology 1984;61(5):622. [17] Olsen RJ, Bromberg BB, Zimmerman TJ. Apneic spells associated with timolol therapy in a neonate. Am J Ophthalmol 1979;88: [18] Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001;5: [19] Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004;18:24 6. [20] Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr 2004;43: [21] Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. J Pediatr 2001;138: [22] Freedman SF. Medical and surgical treatments for childhood glaucomas. In: Epstein DL, Allingham RR, Schuman JS, editors. Chandler and Grant s glaucoma. 4th edition. Baltimore, MD7 Williams & Wilkins; p [23] Raab EL. Congenital glaucoma. Persp Ophthalmol 1978;2: [24] Pollack IP, Quigley HA, Harbin TS. The Ocusert pilocarpine system: advantages and disadvantages. South Med J 1976;69: [] Jones DE, Watson DM. Angle-closure glaucoma precipitated by the use of phospholine iodide for esotropia in child. Br J Ophthalmol 1967;51: [26] Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS 1999;3:33 9. [27] Yang CB, Freedman SF, Myers JS, et al. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol 1998; 126: [28] Altuna JC, Greenfield DS, Wand M, et al. Latanoprost
8 468 maris et al in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J Glaucoma 1999;8: [29] Ong T, Chia A, Nischal KK. Latanoprost in port wine stain related paediatric glaucoma. Br J Ophthalmol 2003;87: [30] Enyedi LB, Freeman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol 2002; 47(Suppl):S [31] Netland PA, Kolker AE. Osmotic drugs. In: Netland PA, Allen RC, editors. Glaucoma medical therapy: principles and management. San Francisco, CA7 American Academy of Ophthalmology; p [32] Chung CY, Kwok AK, Chung KL. Use of ophthalmic medications during pregnancy. Hong Kong Med J 2004;10: [33] Becker B, Friedenwald JS. Clinical aqueous outflow. Arch Ophthalmol 1953;50: [34] Kass MA, Sears ML. Hormonal regulation of intraocular pressure. Surv Ophthalmol 1977;22: [35] Sunness JS. The pregnant woman s eye. Surv Ophthalmol 1988;32: [36] Qureshi IA, Xi XR, Wu XD. Intraocular pressure trends in pregnancy and in the third trimester hypertensive patients. Acta Obstet Gynecol Scand 1996; 75: [37] Kooner K, Zimmerman T. Antiglaucoma therapy during pregnancy part II. Ann Ophthalmol 1988;20: [38] Salamalekis E, Kassanos D, Hassiakos D, et al. Intra/ extra-amniotic administration of prostaglandin F2a in fetal death, missed and therapeutic abortions. Clin Exp Obstet Gynecol 1990;17: [39] De Santis M, Lucchese A, Carducci B, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol 2004;138(2): [40] Lustgarten J, Podos S. Topical timolol and the nursing mother. Arch Ophthalmol 1983;101:
Medical Treatment in Pediatric Glaucoma
Medical Treatment in Pediatric Glaucoma By Nader Bayoumi, MD Lecturer of Ophthalmology Ophthalmology Department Alexandria University Alexandria, Egypt ESG 2012 Pediatric glaucoma is a surgical disease
More informationVI.2.2 Summary of treatment benefits
EU-Risk Management Plan for Bimatoprost V01 aetiology), both OAG and ACG can be secondary conditions. Secondary glaucoma refers to any case in which another disorder (e.g. injury, inflammation, vascular
More informationOCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level.
OCULAR PHARMACOLOGY GLAUCOMA increased intraocular pressure normally 12 20 mm Hg. when to Tx no fixed level. literature sets ~21 mm Hg as upper limit of normal. some safe at 30 mm Hg some may have damage
More informationA. Incorrect! Acetazolamide is a carbonic anhydrase inhibitor given orally or by intravenous injection.
Pharmacology - Problem Drill 20: Drugs that Treat Glaucoma Question No. 1 of 10 1. is a topical carbonic anhydrase inhibitor. Question #01 (A) Acetazolamide (B) Clonidine (C) Dorzolamide (D) Apraclonidine
More information8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension
3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Isopto Carpine safely and effectively. See full prescribing information for Isopto Carpine. Isopto
More informationBETAGAN Allergan Levobunolol HCl Glaucoma Therapy
BETAGAN Allergan Levobunolol HCl Glaucoma Therapy Action And Clinical Pharmacology: Levobunolol is a noncardioselective beta- adrenoceptor antagonist, equipotent at both beta1 and beta2 receptors. Levobunolol
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 May 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 May 2008 COSOPT 20 mg/5 mg/ml, eye drops, solution in single dose container Box of 60 0.2 ml single dose containers
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Epidemiology of the disease Incidence and prevalence Increased pressure in the eye occurs in more than 100 million people, and
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationEast and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults
East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults Introduction Glaucoma is a group of eye diseases causing optic nerve damage. In most cases
More informationGlaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?
Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the
More informationFinancial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy
The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy Danica J. Marrelli, OD, FAAO University of Houston College of Optometry Financial Disclosure I have received I have received speaking
More informationBRIMOPRESS-T EYE DROPS. COMPOSITION Each ml of BRIMOPRESS-T EYE DROPS contains. Brimonidine Tartarate 0.2% Timolol Maleate 0.5%
BRIMOPRESS-T EYE DROPS COMPOSITION Each ml of BRIMOPRESS-T EYE DROPS contains Brimonidine Tartarate 0.2% Timolol Maleate 0.5% BRIMOPRESS-T ophthalmic solution is a combination of Brimonidine Tartrate,
More informationThe treatment benefit of latanoprost has not been studied in the following populations/patients:
6.1. ELEMENTS FOR A PUBLIC SUMMARY 6.1.1. Overview of Disease Epidemiology Glaucoma is the second leading cause of blindness worldwide, and affects about 66.8 million people worldwide i,ii. Glaucoma can
More informationIOPIDINE 1% IOPIDINE 0.5% Alcon Apraclonidine HCl Controls Postsurgical Intraocular Pressure Glaucoma Therapy
IOPIDINE 1% IOPIDINE 0.5% Alcon Apraclonidine HCl Controls Postsurgical Intraocular Pressure Glaucoma Therapy Action And Clinical Pharmacology: Apraclonidine is a relatively selective alpha adrenergic
More informationManaging the Patient with POAG
Managing the Patient with POAG Vision Institute Annual Fall Conference Mitchell W. Dul, OD, MS, FAAO mdul@sunyopt.edu Richard J. Madonna, MA, OD, FAAO rmadonna@sunyopt.edu Ocular Hypertension (OHT) Most
More informationSummary of the risk management plan (RMP) for Izba (travoprost)
EMA/14138/2014 Summary of the risk management plan (RMP) for Izba (travoprost) This is a summary of the risk management plan (RMP) for Izba, which details the measures to be taken in order to ensure that
More informationAPPROVED PACKAGE INSERT FOR XALATAN EYE DROPS. Each millilitre contains latanoprost 50 µg and benzalkonium chloride 0,02 % m/v as preservative.
SCHEDULING STATUS: S4 APPROVED PACKAGE INSERT FOR XALATAN EYE DROPS PROPRIETARY NAME (and dosage form): XALATAN Eye Drops COMPOSITION: Each millilitre contains latanoprost 50 µg and benzalkonium chloride
More informationUpdate on Rhopressa TM QD (netarsudil ophthalmic solution) 0.02% and Roclatan TM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.
Update on Rhopressa TM QD (netarsudil ophthalmic solution) 0.02% and Roclatan TM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 1 Important Information Any discussion of the potential use or
More informationBrightFocus Foundation is the new name for American Health Assistance Foundation.
In this section, you will find the following: Glaucoma Medications Laser Therapies Conventional Surgical Procedures In the second section, you will find information on how to search for potential treatments
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More informationPhospholine Iodide (echothiophate iodide for ophthalmic solution)
Phospholine Iodide (echothiophate iodide for ophthalmic solution) Rx Only DESCRIPTION Chemical name: (2-mercaptoethyl) trimethylammonium iodide O,O-diethyl phosphorothioate Structural formula Echothiophate
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
Guidelines for the medical treatment of chronic open angle glaucoma and ocular hypertension Summary: DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Diagnosis and management of ocular hypertension (OHT)
More informationTreatments for Open-Angle Glaucoma. A Review of the Research for Adults
Treatments for Open-Angle Glaucoma A Review of the Research for Adults Is This Information Right for Me? Yes, this information is for you if: Your eye doctor has said that you have open-angle glaucoma,
More informationLOWPROST Eye Drops (Bimatoprost Ophthalmic Solution 0.01%)
Published on: 14 Apr 2017 LOWPROST Eye Drops (Bimatoprost Ophthalmic Solution 0.01%) For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only Composition Each ml contains: Bimatoprost...
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The term ocular hypertension usually refers to any situation in which the pressure inside the eye, called intraocular pressure,
More informationIOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)
This overview of 2% eye drops was presented by Dr. Ravin N. Das, at Hotel Satya Ashoka, on 19-6-2004 in place of Dr. H. S. Ray due to unforseen circumstances. This dinner meeting was sponsored by Cipla
More informationDrugs for glaucoma. Ivan Goldberg, Eye Associates and Glaucoma Service, Sydney Eye Hospital and the Save Sight Institute, University of Sydney, Sydney
Drugs for glaucoma Ivan Goldberg, Eye Associates and Glaucoma Service, Sydney Eye Hospital and the Save Sight Institute, University of Sydney, Sydney SYNOPSIS Older drugs for glaucoma reduce intra-ocular
More informationBuilding a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. Company Overview June 2-3, 2015
Building a Major Ophthalmic Pharmaceutical Company Aerie Pharmaceuticals, Inc. Company Overview June 2-3, 2015 1 Important Information Any discussion of the potential use or expected success of our product
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
NEW ZEALAND DATA SHEET 1. PRODUCT NAME ISOPTO CARPINE pilocarpine hydrochloride eye drops 1% ISOPTO CARPINE pilocarpine hydrochloride eye drops 2% ISOPTO CARPINE pilocarpine hydrochloride eye drops 4%
More informationEfficacy of latanoprost in management of chronic angle closure glaucoma. Kumar S 1, Malik A 2 Singh M 3, Sood S 4. Abstract
Original article Efficacy of latanoprost in management of chronic angle closure glaucoma Kumar S 1, Malik A 2 Singh M 3, Sood S 4 1 Associate Professor, 2 Assistant Professor, 4 Professor, Department of
More informationSouth East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway
Proceed to 2 nd line treatment if further reduction in IOP required and there is good response to PGAs or (& no South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension
More informationElements for a public summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Glaucoma is an eye disease that can result in damage to the optic nerve and loss of vision (blindness). It is the major cause
More informationKEY MESSAGES. Details of the evidence supporting these recommendations can be found in the above CPG, available on the following websites:
QUICK REFERENCE FOR HEALTHCARE PROVIDERS KEY MESSAGES 1. Glaucoma is a chronic eye disease that damages the optic nerve, & can result in serious vision loss and irreversible blindness. 2. Glaucoma diagnosis
More informationINDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.
Page 1 of 5 SCHEDULING STATUS Schedule 3 PROPRIETARY NAME (AND DOSAGE FORM) ACULAR 0,5 % COMPOSITION ACULAR 0,5 % contains: Preservatives: Benzalkonium chloride 0,01 % m/v Disodium edetate 0,1 % m/v PHARMACOLOGICAL
More informationThe Place for Selective Laser Trabeculoplasty in the Management of Glaucoma
The Place for Selective Laser Trabeculoplasty in the Management of Glaucoma Jung-Il Moon, M.D., PhD Glaucoma Services Catholic Eye Center St. Mary s s Hospital The Catholic Univ. of Korea Treatment of
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Studies estimated that 3-6 million people in the United States alone, including 4-10% of the population older than 40 years, have
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 11 Oxytocics and Ergot Alkaloids. LESSON ASSIGNMENT Paragraphs 11-1 through 11-13. LESSON OBJECTIVES After completing this lesson, you should be able to: 11-1. Given a group of
More information8/30/2018. Eye Disorders. Patrick Sarte. Anatomy of the Eye Uveitis Scleritis vs. Episcleritis Glaucoma Retinal Findings Eyelids
Eye Disorders Patrick Sarte Anatomy of the Eye Uveitis Scleritis vs. Episcleritis Glaucoma Retinal Findings Eyelids 1 Anatomy of the Eye Anatomy of the Eye 2 Anatomy of the Eye 3 4 A 26 year old woman
More informationBrimonidine/timolol Version 1.2, 16Oct, Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The estimated number of people with vision loss from glaucoma range from 5.2 to 6.7 million. This is approximately 10% of the
More informationVolume 9; Number 6 May 2015 PRESCRIBING FOR CHRONIC OPEN ANGLE GLAUCOMA (COAG) AND OCULAR HYPERTENSION (OHT)
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationDivakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16
Divakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16 Pathophysiology of glaucoma Consider risk factors of glaucoma Understand the side effects of glaucoma medications Diagnostic testing Leading cause
More informationRevised: 07/2017. LUMIGAN (bimatoprost ophthalmic solution) 0.01% for topical ophthalmic use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LUMIGAN 0.01% safely and effectively. See full prescribing information for LUMIGAN 0.01%. LUMIGAN
More information[TRAVOPROST] 40 MICROGRAMS/ML, EYE DROPS, SOLUTION RISK MANAGEMENT PLAN. TRAVOPR-v
[TRAVOPROST] 40 MICROGRAMS/ML, EYE DROPS, SOLUTION RISK MANAGEMENT PLAN TRAVOPR-v2-270214 VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Studies estimated that 3-6 million people
More informationClass Update with New Drug Evaluation: Glaucoma Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Systemic Effect Of Topical Timolol On Some Cardiovascular Parameters In Owerri Municipality
ISPUB.COM The Internet Journal of Third World Medicine Volume 5 Number 1 The Systemic Effect Of Topical Timolol On Some Cardiovascular Parameters In Owerri Municipality G Oze, M Emegwamuo, P Eleanya, H
More informationVision Health: Conditions, Disorders & Treatments GLAUCOMA
Vision Health: Conditions, Disorders & Treatments GLAUCOMA Glaucoma is a disease of the optic nerve, which transmits the images you see from the eye to the brain. The optic nerve is made up of many nerve
More informationLong Term Care Formulary RS 14. RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5
RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5 PREAMBLE Significance: Glaucoma occurs in 1-2% of white people aged over 40 years, rising to 5% at 70 years and exponentially with advancing
More informationALPHAGAN P 1.5 Eye Drops
ALPHAGAN P 1.5 Eye Drops NAME OF THE DRUG The active constituent of ALPHAGAN P 1.5 eye drops is brimonidine tartrate. CAS Registry No.: 79570-19-7 (structure of brimonidine tartrate) DESCRIPTION Brimonidine
More informationPatients with ocular hypertension or
... REPORTS... An Economic Analysis of Switching to Latanoprost from a β-blocker or Adding Brimonidine or Latanoprost to a β-blocker in Open-Angle Glaucoma or Ocular Hypertension William C. Stewart, MD;
More informationLUMIGAN (bimatoprost ophthalmic solution) 0.03% for topical ophthalmic use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LUMIGAN 0.03% safely and effectively. See full prescribing information for LUMIGAN 0.03%. LUMIGAN
More informationScience & Technologies. UNWANTED SIDE EFFECTS OF TRAVOPROST Gazepov Strahil 1, Iljaz Ismaili 2, Goshevska Dashtevska Emilija 2
UNWANTED SIDE EFFECTS OF TRAVOPROST Gazepov Strahil 1, Iljaz Ismaili 2, Goshevska Dashtevska Emilija 2 1 Clinical Hospital, Shtip 2 University Eye Clinic,Skopje Introduction: Glaucoma is a chronical progressive
More informationCompleted Clinical Research Trials Monte Dirks, M.D.
Completed Clinical Research Trials Monte Dirks, M.D. Monte Dirks, M.D. - Primary Investigator Norfloxacin -Merck (1986) Safety and efficacy of norfloxacin vs. tobramycin in the treatment of external ocular
More informationDrug Prescribing Pattern & Adverse Drug Effects Of Anti Glaucoma Medication for Primary Glaucoma at Tertiary Care Hospital
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 11 Ver. III (Nov. 2017), PP 36-41 www.iosrjournals.org Drug Prescribing Pattern & Adverse Drug
More informationCLINICAL SCIENCES. Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents
Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents Todd L. Maus, MD; Cherie Nau; Richard F. Brubaker, MD CLINICAL SCIENCES Objective: To compare the mechanism
More information3 DOSAGE FORMS AND STRENGTHS
PATADAY- olopatadine hydrochloride solution/ drops Alcon Laboratories, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PATADAY safely
More informationeffect of previous argon laser trabeculoplasty
Graefe s Arch Clin Exp Ophthalmol (2006) 244: 1073 1076 CLINICAL INVESTIGATION DOI 10.1007/s00417-005-0198-x Esther Arranz-Marquez Miguel A. Teus Effect of previous argon laser trabeculoplasty on the ocular
More informationAbbreviated Class Update: Ophthalmics, Glaucoma agents. Month/Year of Review: August 2012 End date of literature search: June 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGlaucoma: target intraocular pressures and current treatments James McAllister FRCS, FRCOphth
Glaucoma: target intraocular pressures and current treatments James McAllister FRCS, FRCOphth Skyline Imaging Ltd Our Drug review of glaucoma management describes the use of target intraocular pressures
More informationCAS Registry No.:
ALPHAGAN Eye Drops NAME OF THE MEDICINE The active constituent of ALPHAGAN eye drops is brimonidine tartrate. CAS Registry No.: 79570-19-7 (structure of brimonidine tartrate) DESCRIPTION Brimonidine tartrate
More informationPRESCRIBING INFORMATION MYDFRIN * Phenylephrine Hydrochloride Ophthalmic Solution. Vasoconstrictor and Mydriatic for Use in Ophthalmology
PRESCRIBING INFORMATION MYDFRIN * Phenylephrine Hydrochloride Ophthalmic Solution Vasoconstrictor and Mydriatic for Use in Ophthalmology Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd., Dorval,
More informationDATA SHEET. Clinical studies have shown mean intraocular pressure decreases of up to 9 mmhg.
DATA SHEET NAME OF MEDICINE LUMIGAN (bimatoprost) 0.3 mg/ml eye drops Presentation LUMIGAN (bimatoprost) eye drops are a clear, isotonic, colourless, sterile ophthalmic solution. Bimatoprost is a white
More informationPractical approach to medical management of glaucoma DR. RATHINI LILIAN DAVID
Practical approach to medical management of glaucoma DR. RATHINI LILIAN DAVID Glaucoma is one of the major causes of visual loss worldwide. The philosophy of glaucoma management is to preserve the visual
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationALPHAGAN P 1.5 Eye Drops
ALPHAGAN P 1.5 Eye Drops NAME OF THE MEDICINE The active constituent of ALPHAGAN P 1.5 eye drops is brimonidine tartrate. CAS Registry No.: 79570-19-7 (structure of brimonidine tartrate) DESCRIPTION Brimonidine
More informationAbbreviated Update: Ophthalmic Glaucoma Agents
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Update: Ophthalmic Glaucoma Agents Month/Year
More informationClass Update with New Drug Evaluation: Glaucoma Drugs
Class Update with New Drug Evaluation: Glaucoma Drugs Date of Review: May 2018 Date of Last Review: January 2015 End Date of Literature Search: 02/26/2018 Generic Name: latanoprostene bunod Brand Name
More informationDrugs Affecting the Autonomic Nervous System-2 Cholinergic agents
Drugs Affecting the Autonomic Nervous System-2 Cholinergic agents Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Cholinergic agents, Cholinomimetic drugs,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS Latanoprost Mylan 50 microgram/ml eye drops solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 50 micrograms
More informationGlaucoma. Glaucoma. Optic Disc Cupping
Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville
More informationLATANOPROST XALATAN 50 mcg/ml Ophthalmic Solution
1.0. THERAPEUTIC CATEGORY Anti-Glaucoma 2.0 DESCRIPTION LATANOPROST XALATAN 50 mcg/ml Ophthalmic Solution Latanoprost is a prostaglandin F 2α analogue. Its chemical name is isopropyl-(z)- 7[(1R, 2R, 3R,
More informationLatanoprost 0.005% v/s Timolol Maleate 0.5% Pressure Lowering Effect in Primary Open Angle Glaucoma
Original Article Latanoprost 0.005% v/s Timolol Maleate 0.5% Pressure Lowering Effect in Primary Open Angle Glaucoma Arshad Ali Lodhi, Khalid Iqbal Talpur, Mahtab Alam Khanzada Pak J Ophthalmol 2008, Vol.
More informationClass Update with New Drug Evaluation: Glaucoma Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationA Short-term Study of the Additive Effect of Latanoprost 0.005% and Brimonidine 0.2%
A Short-term Study of the Additive Effect of Latanoprost 0.005% and Brimonidine 0.2% Haydar Erdoğan, İlker Toker, Mustafa Kemal Arıcı, Ahmet Aygen and Ayşen Topalkara Department of Ophthalmology, School
More informationPRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. IOPIDINE (apraclonidine hydrochloride) Eye Drops 0.5%
PRODUCT INFORMATION IOPIDINE (apraclonidine hydrochloride) Eye Drops 0.5% NAME OF THE MEDICINE IOPIDINE Eye Drops 0.5% contains apraclonidine hydrochloride, an alpha-adrenergic agonist, in a sterile isotonic
More informationNEW ZEALAND DATA SHEET
TRUSOPT 2% Ophthalmic Solution dorzolamide hydrochloride 1 Trusopt 2% Opthalmic Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1mL of TRUSOPT 2% contains 20 mg dorzolamide (22.3 mg of dorzolamide
More informationOphthalmological preparations
Ophthalmological preparations Administration of eye preparations Preparations for the eye should be sterile when issued. Use of single-application containers is preferable; multiple-application preparations
More informationCOOCH(CH 3 ) 2. Sixty four isomers of latanoprost are possible, however, for XALATAN it is purified as a single isomer.
Product Information XALATAN, Eye Drops (Latanoprost 50 micrograms/ml) NAME OF THE DRUG latanoprost OH COOCH(CH 3 ) 2 OH OH The chemical name of latanoprost is Isopropyl-(Z)-7[(1R,2R,3R,5S) 3,5-dihydroxy-2-
More informationBy Dr.Asmaa Al sanjary
By Dr.Asmaa Al sanjary Preterm delivery is defined by a birth occurring before 37 completed weeks of gestation. Prematurity is multifactorial and its incidence has increased during the last decade in most
More informationPGAs. Glaucoma Pharmacology A-Z. Selecting Therapy. PGAs Prostaglandin analogs. Prostaglandin Side Effects 1/6/2014
PGAs Glaucoma Pharmacology A-Z Eric E. Schmidt, O.D. Omni Eye Specialists Wilmington, NC schmidtyvision@msn.com QHS dosing Long duration of action Flatten diurnal curve Effective on trough and peak IOP
More informationRole of Initial Preoperative Medical Management in Controlling Post-Operative Anterior Uveitis in Patients of Phacomorphic Glaucoma
Original Article Role of Initial Preoperative Medical Management in Controlling Post-Operative Anterior Uveitis in Patients of Phacomorphic Glaucoma Irfan Qayyum Malik, M. Moin, A. Rehman, Mumtaz Hussain
More informationThe Uniocular Drug Trial and Second-Eye Response to Glaucoma Medications
The Uniocular Drug Trial and Second-Eye Response to Glaucoma Medications Tony Realini, MD, 1 Robert D. Fechtner, MD, 2 Sean-Paul Atreides, MD, 3 Stephen Gollance, MD 2 Purpose: To determine if the intraocular
More informationROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, for topical ophthalmic use Initial U.S. Approval: 2019
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ROCKLATAN safely and effectively. See full prescribing information for ROCKLATAN. ROCKLATAN (netarsudil
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT LUMIGAN 0.1 mg/ml eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of solution contains 0.1 mg bimatoprost.
More informationPublic Assessment Report. Paediatric data. COSOPT eye drops solution Dorzolamide Hydrochloride Timolol Maleate
Public Assessment Report Paediatric data COSOPT eye drops solution Dorzolamide Hydrochloride Timolol Maleate Marketing Autorisation Holder: Merck Sharp & Dohme Rapporteur: Co-Rapporteur: Paediatric assessment
More informationFor patients with elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT)
The First and Only Preservative-Free Prostaglandin Once daily, preservative-free For patients with elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) Powerful
More informationGlaucoma. How is Glaucoma Diagnosed? Glaucoma Testing
Glaucoma How is Glaucoma Diagnosed? Glaucoma Testing There is no single test for glaucoma. The diagnosis is made by evaluating the patient from a number of perspectives, using specialized instruments.
More informationInternal Document code 1 iop041217inz
NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE (apraclonidine hydrochloride) Eye Drops 0.5%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Iopidine Eye Drops 0.5% contains apraclonidine hydrochloride
More informationVisual Impairment Secondary to Congenital Cataracts: A Case Report
Visual Impairment Secondary to Congenital Cataracts: A Case Report Karen Kehbein, OD Big Rapids, Michigan Abstract Background: Congenital cataracts can lead to severe effects on the development of the
More informationPRODUCT INFORMATION. XALATAN (Latanoprost) NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY
PRODUCT INFORMATION XALATAN (Latanoprost) NAME OF THE MEDICINE The chemical name of latanoprost is isopropyl-(z)-7[(1r,2r,3r,5s) 3,5-dihydroxy-2-[(3R)-3- hydroxy-5-phenyl-1-pentyl]cyclopentyl]-5-heptenoate,
More informationTransient Intraocular Pressure Elevation after Trabeculotomy and its Occurrence with Phacoemulsification and Intraocular Lens Implantation
Transient Intraocular Pressure Elevation after Trabeculotomy and its Occurrence with Phacoemulsification and Intraocular Lens Implantation Masaru Inatani*, Hidenobu Tanihara, Takahito Muto*, Megumi Honjo*,
More informationGonioscopy and 3-Mirror Retinal Evaluation Workshop Edeline Lu, O.D., FAAO Benedicte Gonzalez, O.D., MPH, FAAO Tina Zheng, O.D.
Gonioscopy and 3-Mirror Retinal Evaluation Workshop Edeline Lu, O.D., FAAO Benedicte Gonzalez, O.D., MPH, FAAO Tina Zheng, O.D., FAAO Please silence all mobile devices and remove items from chairs so others
More informationNEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 0.1 mg or 0.3 mg of bimatoprost.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME BIMATOPROST ACTAVIS, Eye drops, solution, 0.1 mg/ml and 0.3 mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 0.1 mg or 0.3 mg of bimatoprost. Excipient
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each ml contains 20 mg dorzolamide (as 22.3 mg of dorzolamide hydrochloride).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Dorzolamide Actavis 20mg/ml Eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 20 mg dorzolamide (as 22.3
More information9 PM Eye Drops (Latanoprost 0.005%)
Published on: 10 Jul 2014 9 PM Eye Drops (Latanoprost 0.005%) Composition Each ml contains: Latanoprost... 50 mcg Benzalkonium Chloride, NF... 0.02%w/v (as preservative) aqueous vehicle... q.s. Dosage
More informationROBERT L. SHIELDS, M.D. GLAUCOMA SURGERY AND TREATMENT
1 CURRICULUM VITAE ROBERT L. SHIELDS, M.D. GLAUCOMA SURGERY AND TREATMENT University of Colorado Health Eye Center Cherry Creek 2000 South Colorado Boulevard Annex Building, Suite 100 Denver, Colorado
More informationTreatments on the Horizon
Latanoprostene bunod (Vesneo) Treatments on the Horizon Dominick L Opitz, OD, FAAO Associate Professor Illinois College of Optometry Valeant (B+L) Nitrous oxide-donating prostaglandin F2-alpha analogue
More informationM Diestelhorst, L-I Larsson,* for The European Latanoprost Fixed Combination Study Group...
199 SCIENTIFIC REPORT A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension
More informationAPO-LATANOPROST EYE DROPS BOTTLE. Isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenyl-1- pentyl]cyclopentyl]-5-heptenoate.
APO-LATANOPROST EYE DROPS BOTTLE NAME OF THE MEDICINE Latanoprost Chemical Name: Isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenyl-1- pentyl]cyclopentyl]-5-heptenoate. Structural Formula:
More informationNew Zealand Data Sheet APO-BIMATOPROST
New Zealand Data Sheet APO-BIMATOPROST Presentation APO-BIMATOPROST is a clear colourless solution. Indications APO-BIMATOPROST is indicated as monotherapy for the reduction of elevated intraocular pressure
More information